Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Cx601

This page shows the latest Cx601 news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Alofisel - previously Cx601 - is approved to treat complex perianal fistulas in adult patients with nonactive or mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at

Latest news

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    CX601 has been classed as an orphan treatment for treating people who don’t respond to drug therapy. ... offers the best capabilities and resources to ensure access to Cx601 to patients worldwide.”.

  • CHMP backs Europe’s first allogeneic stem cell therapy CHMP backs Europe’s first allogeneic stem cell therapy

    Takeda paid 25m upfront for rights to Cx601 for this indication outside the US, pledging another 355m in milestone payments, including 15m on approval by the EMA. ... TiGenix still owns the US rights to Cx601, considered a larger market opportunity for

  • TiGenix’s Crohn's fistulas treatment wins orphan drug status TiGenix’s Crohn's fistulas treatment wins orphan drug status

    The drug - currently known as Cx601 - could potentially treat ‘complex’ perianal fistulas in patients with Crohn’s disease who have had an inadequate response to at least one conventional or biologic ... Meanwhile, TiGenix and partner Takeda has

  • TiGenix cell therapy for Crohn's fistulas shows long-term benefit TiGenix cell therapy for Crohn's fistulas shows long-term benefit

    In ADMIRE-CD, 56% of patients treated with Cx601 and usual supportive care went into remission, compared to 39% of patients who received placebo plus standard care. ... Existing therapies are limited and associated with complications and a high failure

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    authorisation for Cx601, so it was probably a good time for Takeda to make a move. ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead asset, allogeneic expanded adipose-derived stem cells (eASC) locally administered for treatment of

  • Deal Watch July 2016 Deal Watch July 2016

    Other deals where the licensee has committed real upfront money include Takeda's $28m upfront payment for ex-US rights to TiGenix's Cx601, a suspension of allogeneic adipose-derived stem ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Quick links

Infographics

Multimedia